Daily non-political popular news in brief.

Herceptin does not increase heart failure in patients long-term

06-03-2007 · EurekAlert!

Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.

Keywords: herceptin, heart, failure, patients, long-term, patient, long, term

« Previous | Next »

Similar news on "Herceptin does not increase heart failure in patients long-term":

Implant device effectively maintains heart function for transplant-listed patients
03-27-2007 · EurekAlert!
Whether a patient is awaiting a heart transplant or living with chronic heart failure, cardiologists are continuously looking for new therapies that address short-term and/or long-term needs of chronically impaired cardiac patients. Research presented today at the American College of Cardiology's 56th Annual Scientific Session reviewed new treatments and interventions, including LVAD implantation and diuretic therapies to support left ventricular function in severely compromised cardiovascular patients.
Similar news · Read more »
Herceptin does not increase heart failure in patients long term
06-03-2007 · EurekAlert!
Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early stage breast cancer did not increase over time according to a five-year follow up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.
Similar news · Read more »
Go team -- 2 kinds of teamwork improves care for chronic heart failure
02-02-2007 · EurekAlert!
Active patient involvement during treatment of chronic heart failure, coupled with partnership with healthcare team members to provide care consistent with evidence-based guidelines, dramatically improves quality of care for chronic heart failure patients according to a study by researchers from the Indiana University School of Medicine, the Regenstrief Institute and the Roudebush VA Medical Center.
Similar news · Read more »
New study reports improved treatment and reduced mortality for patients with heart failure
05-01-2007 · EurekAlert!
UCLA researchers tracked heart failure in-hospital patient trends from 2002 to 2004 for 285 hospitals nationwide and found significant changes in treatment patterns and quality-of-care indicators that paralleled improvements in clinical outcomes and mortality.
Similar news · Read more »
Seven-point system gauges seriousness of heart failure in elderly
11-09-2006 · EurekAlert!
A simple points system may soon help guide treatment of elderly heart failure patients. Researchers at Washington University School of Medicine in St. Louis found that by counting how many of seven easy-to-obtain health factors a patient has, physicians can estimate the patient's risk of dying.
Similar news · Read more »
Disease management programs improve long-term outcomes
03-27-2007 · EurekAlert!
More than 30 percent of patients who suffer heart failure die within one year, but education and support programs have been shown to improve that statistic. According to two studies presented today at the American College of Cardiology’s 56th Annual Scientific Session, education and support programs designed to care for high-risk cardiac patients with more direct interaction and guidance were successful in both reducing hospital visits and increasing heart failure patients' chances of long-term survival.
Similar news · Read more »
EVEREST data on use of tolvaptan published in JAMA and featured at ACC
03-27-2007 · EurekAlert!
Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial EVEREST published in the March 28 issue of JAMA and presented at ACC.
Similar news · Read more »
Initiative to improve heart failure care at nation's hospitals makes major gains
07-23-2007 · EurekAlert!
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients. It also resulted in favorable trends for in-hospital and post-discharge mortality rates.
Similar news · Read more »
Study finds limitations in publicly reported quality-of-care indicators for heart-failure patients
01-02-2007 · EurekAlert!
Researchers reported that all five standard hospital-based performance measures used to gauge quality-of-care for hospitalized heart-failure patients may not be the best benchmarks since none were significant predictors of patient mortality during the critical first 60 to 90 days immediately following hospital discharge.
Similar news · Read more »
Hospitalized heart failure patients may benefit from oral tolvaptan
03-25-2007 · EurekAlert!
A diagnosis of worsening acute decompensated heart failure (ADHF) is characterized by the development of dyspnea (shortness of breath) associated with the rapid accumulation of fluid in the lungs. Patients who are hospitalized with ADFA need rapid and sustained fluid retention without risking renal dysfunction. Tolvaptan has been shown to achieve rapid and sustained results in this patient population, according to a study presented today at the American College of Cardiology’s 56th Annual Scientific Session.
Similar news · Read more »